MULLERIAN-INHIBITING SUBSTANCE IS PRESENT IN EMBRYONIC TESTES OF DOGS WITH PERSISTENT MULLERIAN DUCT SYNDROME

被引:27
|
作者
MEYERSWALLEN, VN
LEE, MM
MANGANARO, TF
KURODA, T
MACLAUGHLIN, D
DONAHOE, PK
机构
[1] CORNELL UNIV,COLL VET MED,JA BAKER INST,ITHACA,NY 14853
[2] CORNELL UNIV,COLL VET MED,DEPT CLIN SCI,ITHACA,NY 14853
[3] MASSACHUSETTS GEN HOSP,DEPT PEDIAT SURG,BOSTON,MA 02114
[4] MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114
关键词
D O I
10.1095/biolreprod48.6.1410
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mullerian Inhibiting Substance (MIS) causes regression of the Mullerian ducts during a critical period in embryonic development in male mammals. In Persistent Mullerian Duct Syndrome (PMDS), an autosomal recessive trait in humans and dogs, the Mullerian ducts fail to regress in otherwise normal males. Previously we reported that PMDS-affected dogs produce bioactive testicular MIS postnatally. The purpose of the present study was to determine whether PMDS-affected canine embryos appropriately express MIS mRNA and protein during the critical period for Mullerian duct regression. Homozygous (PMDS-affected) and normal canine embryos were removed from timed pregnancies. Gonadal sex and the degree of Mullerian duct regression were determined from histologic sections. Positive immunohistochemical staining for MIS was found in testis sections of PMDS-affected and normal male embryos. A 1.8-kb MIS mRNA transcript was detected in testes of PMDS-affected males and normal male embryos and neonates. Furthermore, equal amounts of MIS mRNA transcript were detected in testes of PMDS-affected embryos and normal male littermates during the critical period for Mullerian duct regression. These data support a hypothesis of target organ resistance, such as an abnormality in the putative MIS receptor, as the etiology of the defect in this dog model.
引用
收藏
页码:1410 / 1418
页数:9
相关论文
共 50 条
  • [1] MULLERIAN INHIBITING SUBSTANCE IS PRESENT IN TESTES OF DOGS WITH PERSISTENT MULLERIAN DUCT SYNDROME
    MEYERSWALLEN, VN
    DONAHOE, PK
    UENO, S
    MANGANARO, TF
    PATTERSON, DF
    BIOLOGY OF REPRODUCTION, 1989, 41 (05) : 881 - 888
  • [2] MULLERIAN-INHIBITING SUBSTANCE
    BASHIR, MS
    WELLS, M
    JOURNAL OF PATHOLOGY, 1995, 176 (02): : 109 - 110
  • [3] MULLERIAN-INHIBITING SUBSTANCE - AN UPDATE
    DONAHOE, PK
    BUDZIK, GP
    TRELSTAD, R
    MUDGETTHUNTER, M
    FULLER, A
    HUTSON, JM
    IKAWA, H
    HAYASHI, A
    MACLAUGHLIN, D
    RECENT PROGRESS IN HORMONE RESEARCH, 1982, 38 : 279 - 326
  • [4] INSENSITIVITY OF THE CHICK-EMBRYO MULLERIAN DUCT TO HUMAN RECOMBINANT MULLERIAN-INHIBITING SUBSTANCE
    WENIGER, JP
    CATE, RL
    ZEIS, A
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1992, 8 (01) : 73 - 77
  • [5] GONADOTROPIN CONTROL OF MULLERIAN-INHIBITING SUBSTANCE
    BERCU, BB
    MORIKAWA, Y
    JACKSON, IMD
    DONAHOE, PK
    PEDIATRIC RESEARCH, 1979, 13 (02) : 142 - 142
  • [6] MULLERIAN-INHIBITING SUBSTANCE - AN UPDATE - DISCUSSION
    PECK, EJ
    DONAHOE, PK
    SHAPIRO, J
    GLASSER, S
    BULLOCK, L
    LARNER, J
    FINDLAY, JK
    RAJ, MHG
    PAPKOFF, H
    BUDZIK, GP
    AHREN, K
    BLOSSEY, HC
    POMERANTZ, DK
    MOWSZOWICZ, I
    MONDER, C
    PLYMATE, SR
    ROSENWAKS, Z
    CROWLEY, WF
    NICOLL, CS
    RECENT PROGRESS IN HORMONE RESEARCH, 1982, 38 : 326 - 330
  • [7] Serum mullerian-inhibiting substance in Down's syndrome pregnancies
    Seifer, David B.
    MacLaughlin, David T.
    Cuckle, Howard S.
    HUMAN REPRODUCTION, 2007, 22 (04) : 1017 - 1020
  • [8] IDENTIFICATION OF A RECEPTOR FOR HUMAN MULLERIAN-INHIBITING SUBSTANCE
    CATLIN, EA
    EZZELL, RM
    DONAHOE, PK
    GUSTAFSON, ML
    SON, EV
    MACLAUGHLIN, DT
    ENDOCRINOLOGY, 1993, 133 (06) : 3007 - 3013
  • [9] MULLERIAN-INHIBITING SUBSTANCE AS A CANCER THERAPEUTIC AGENT
    FULLER, AF
    KRANE, IM
    BUKZIK, G
    DONAHOE, PK
    GYNECOLOGIC ONCOLOGY, 1985, 20 (02) : 254 - 254
  • [10] THE IN-VIVO ROLES OF MULLERIAN-INHIBITING SUBSTANCE
    BEHRINGER, RR
    CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, VOL 29, 1994, 29 : 171 - 187